参考文献/References:
[1] MacIntyre C,Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy[J]. Circulation,2016,133(19):1901-1905.
[2] Masri A,Kanj M,Thamilarasan M,et al. Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation:a survival meta-analysis[J]. Cardiovasc Diagn Ther,2017,7(1):36-44.
[3] Guttmann OP,Rahman MS,O’Mahony C,et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:systematic review[J]. Heart,2014,100(6):465-472.
[4] Maron BJ,Ommen SR,Semsarian C,et al. Hypertrophic cardiomyopathy:present and future,with translation into contemporary cardiovascular medicine[J]. J Am Coll Cardiol,2014,64(1):83-99.
[5] Maron BJ,Rowin EJ,Casey SA,et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies[J]. J Am Coll Cardiol,2015,65(18):1915-1928.
[6] Lee SE,Park JK,Uhm JS,et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy[J]. Heart,2017,103(19):1496-1501.
[7] Kubo T,Kitaoka H,Okawa M,et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study[J]. Circ J,2009,73(9):1599-1605.
[8] Kannel WB,Wolf PA,Benjamin EJ,et al. Prevalence,incidence,prognosis,and predisposing conditions for atrial fibrillation:population-based estimates[J]. Am J Cardiol,1998,82(8A):2N-9N.
[9] Olivotto I,Cecchi F,Casey SA,et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy[J]. Circulation,2001,104(21):2517-2524.
[10] Froehlich L,Meyre P,Aeschbacher S,et al. Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation:a systematic review and meta-analysis[J]. Heart,2019,105(24):1884-1891.
[11] Alphonse P,Virk S,Collins J,et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy:a systematic review[J]. Clin Res Cardiol,2021,110(4):544-554.
[12] Higashikawa M,Nakamura Y,Yoshida M,et al. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation[J]. Jpn Circ J,1997,61(8):673-681.
[13] January CT,Wann LS,Alpert JS,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation,2014,130(23):2071-2104.
[14] January Craig T,Samuel WL,Hugh C,et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Heart Rhythm,2019,16(8):e66-e93.
[15] Authors/Task Force members,Elliott PM,Anastasakis A,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J,2014,35(39):2733-2779.
[16] Maron BJ,Olivotto I,Bellone P,et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2002,39(2):301-307.
[17] Rowin EJ,Hausvater A,Link MS,et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy[J]. Circulation,2017,136(25):2420-2436.
[18] Noseworthy PA,Yao X,Shah ND,et al. Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. J Am Coll Cardiol,2016,67(25):3020-3021.
[19] Lee HJ,Kim HK,Jung JH,et al. Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation[J]. Stroke,2019,50(9):2582-2586.
[20] Arunachalam K,Maan A,Chu A. Atrial fibrillation in hypertrophic cardiomyopathy:evidence-based review about mechanism,complications and management[J]. Crit Pathw Cardiol,2020,19(2):87-89.
[21] Miller C,Maron MS,Estes NAM III,et al. Safety,side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy[J]. Am J Cardiol,2019,123(11):1859-1862.
[22] 赵学军,王东阳. 药物及导管消融治疗肥厚型心肌病合并心房颤动患者疗效及安全性对比研究[J]. 西北国防医学杂志,2017,38(5):324-327.
[23] di Donna P,Olivotto I,Delcrè SD,et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy:impact of age,atrial remodelling,and disease progression[J]. Europace,2010,12(3):347-355.
[24] Bassiouny M,Lindsay BD,Lever H,et al. Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. Heart Rhythm,2015,12(7):1438-1447.
[25] Rozen G,Elbaz-Greener G,Marai I,et al. Utilization and complications of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. J Am Heart Assoc,2020,9(13):e015721.
[26] Chen X,Dong JZ,Du X,et al. Long-term outcome of catheter ablation for atrial fibrillation in patients with apical hypertrophic cardiomyopathy[J]. J Cardiovasc Electrophysiol,2018,29(7):951-957.
[27] Maagh P,Plehn G,Christoph A,et al. Impact of cryoballoon ablation in hypertrophic cardiomyopathy-related heart failure due to paroxysmal atrial fibrillation. A comparative case series[J]. Int J Med Sci,2016,13(9):664-672.
[28] Zhao DS,Shen Y,Zhang Q,et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Europace,2016,18(4):508-520.
[29] Higuchi S,Ejima K,Minami Y,et al. Long-term clinical course after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. Heart Vessels,2019,34(3):527-537.
[30] Liu X,Ouyang F,Mavrakis H,et al. Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy[J]. Europace,2005,7(5):421-427.
[31] Ikenaga H,Nakano Y,Oda N,et al. Radiofrequency catheter ablation is effective for atrial fibrillation patients with hypertrophic cardiomyopathy by decreasing left atrial pressure[J]. J Arrhythm,2017,33(4):256-261.
[32] Dinshaw L,Münkler P,Sch?ffer B,et al. Ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy:treatment strategy,characteristics of consecutive atrial tachycardia and long-term outcome[J]. J Am Heart Assoc,2021,10(3):e017451.
[33] Gaita F,di Donna P,Olivotto I,et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. Am J Cardiol,2007,99(11):1575-1581.
[34] Cao ZJ,Guo XG,Sun Q,et al. Pulmonary vein isolation implemented by second-generation cryoballoon for treating hypertrophic cardiomyopathy patients with symptomatic atrial fibrillation:a case-control study[J]. J Geriatr Cardiol,2020,17(8):476-485.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(5):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[11]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[12]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(5):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[13]余淼 汤宝鹏.肥厚型心肌病合并心房颤动非药物治疗研究进展[J].心血管病学进展,2024,(1):40.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.011]
YU Miao,TANG Baopeng.Non-Pharmacological Treatment of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(5):40.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.011]